AmCad BioMed Corporation reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 13.26 million compared to TWD 27.24 million a year ago. Net loss was TWD 14.11 million compared to net income of TWD 0.029 million a year ago. Basic loss per share from continuing operations was TWD 0.27.
For the nine months, sales was TWD 47.84 million compared to TWD 58.94 million a year ago. Net loss was TWD 33.32 million compared to TWD 19.32 million a year ago. Basic loss per share from continuing operations was TWD 0.63 compared to TWD 0.36 a year ago.